Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Current Deferred Revenue (2021 - 2023)

Pulse Biosciences has reported Current Deferred Revenue over the past 3 years, most recently at $4000.0 for Q1 2023.

  • Quarterly results put Current Deferred Revenue at $4000.0 for Q1 2023, down 75.0% from a year ago — trailing twelve months through Mar 2023 was $4000.0 (down 75.0% YoY), and the annual figure for FY2021 was $16000.0, changed.
  • Current Deferred Revenue for Q1 2023 was $4000.0 at Pulse Biosciences, down from $38000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PLSE hit a ceiling of $38000.0 in Q3 2022 and a floor of $4000.0 in Q1 2023.
  • Median Current Deferred Revenue over the past 3 years was $16000.0 (2021), compared with a mean of $18833.3.
  • Biggest five-year swings in Current Deferred Revenue: soared 442.86% in 2022 and later crashed 75.0% in 2023.
  • Pulse Biosciences' Current Deferred Revenue stood at $16000.0 in 2021, then soared by 137.5% to $38000.0 in 2022, then tumbled by 89.47% to $4000.0 in 2023.
  • The last three reported values for Current Deferred Revenue were $4000.0 (Q1 2023), $38000.0 (Q3 2022), and $32000.0 (Q2 2022) per Business Quant data.